Your browser doesn't support javascript.
loading
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
Thomas F Rogers; Fangzhu Zhao; Deli Huang; Nathan Beutler; Alison Burns; Wan-ting He; Oliver Limbo; Chloe Smith; Ge Song; Jordan Woehl; Linlin Yang; Robert K Abbott; Sean Callaghan; Elijah Garcia; Jonathan Hurtado; Mara Parren; Linghang Peng; James Ricketts; Michael K Ricciardi; Stephen A Rawlings; Davey M Smith; David Nemazee; John R Teijaro; James E Voss; Raiees Andrabi; Bryan Briney; Elise Landais; Devin Sok; Joseph G Jardine; Dennis Burton.
Afiliação
  • Thomas F Rogers; The Scripps Research Institute, UCSD
  • Fangzhu Zhao; The Scripps Research Institute
  • Deli Huang; The Scripps Research Institute
  • Nathan Beutler; The Scripps Research Institute
  • Alison Burns; The Scripps Research Institute
  • Wan-ting He; The Scripps Research Institute
  • Oliver Limbo; IAVI
  • Chloe Smith; The Scripps Research Institute
  • Ge Song; The Scripps Research Institute
  • Jordan Woehl; IAVI
  • Linlin Yang; The Scripps Research Institute
  • Robert K Abbott; La Jolla Institute for Immunology
  • Sean Callaghan; The Scripps Research Institute
  • Elijah Garcia; The Scripps Research Institute
  • Jonathan Hurtado; The Scripps Research Institute
  • Mara Parren; The Scripps Research Institute
  • Linghang Peng; The Scripps Research Institute
  • James Ricketts; The Scripps Research Institute
  • Michael K Ricciardi; George Washington University
  • Stephen A Rawlings; UCSD
  • Davey M Smith; UCSD
  • David Nemazee; The Scripps Research Institute
  • John R Teijaro; The Scripps Research Institute
  • James E Voss; The Scripps Research Institute
  • Raiees Andrabi; The Scripps Research Institute
  • Bryan Briney; The Scripps Research Institute
  • Elise Landais; IAVI
  • Devin Sok; IAVI
  • Joseph G Jardine; IAVI
  • Dennis Burton; The Scripps Research Institute
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-088674
ABSTRACT
The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.
Licença
cc_by
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...